The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
Related to this article
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
Advertisement
Advertisement
Trending on Urology Times
1
Health Canada accepts vibegron submission for overactive bladder
2
Tokyo-172 vs TICE BCG: Eugene Cone, MD, discusses SWOG S1602 findings
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
FDA clears LigaSure RAS Maryland instrument for use with Hugo robotic surgery system
5